Simvastatin 40 mg daily,
does it really help with Reduction of acute exacerbations in moderate-to-severe COPD at high risk?
research showsGrade D, 34 points. In 885 STATCOPE participants, annual exacerbation rates were 1.36 versus 1.39 per person-year (P=0.54). After conditional power reached 5%, the DSMB recommended stopping for futility; formal futility-stopping guidelines were not part of the monitoring plan.
ads claimObservational advantages among statin users cannot replace randomized evidence for adding a statin solely for COPD.
Useful facts when choosing a product
- Patients with cardiovascular disease, diabetes, or another statin indication were excluded.
- This was an 885-participant hard-clinical-outcome RCT that ended for futility on DSMB recommendation.
What the research actually shows
This verdict asks whether adding a statin reduces exacerbations in high-risk COPD. Verdict 2907 asks whether to prescribe oxygen in stable COPD with moderate desaturation, while verdict 2909 asks whether a statin saves critically ill patients with acute respiratory distress syndrome. Verdict 681 gives the same simvastatin an A with 92 points for reducing major vascular events in high-risk cardiovascular patients. The contrast - top grade in cardiovascular prevention but null in two respiratory settings - shows that the value lies in where the drug is used, not whether the drug is globally good or bad. Four-gate review: ① Interim-boundary stopping ② listed item ③ the source states, "formal guidelines for stopping the study owing to futility were not part of the monitoring plan"; the DSMB recommended futility stopping after conditional power reached 5%, not upon crossing a formal boundary ④ without a formal stopping boundary, the clause 88 exception does not apply, so it is not counted. ① Recruitment-shortfall termination ② listed item ③ the reason for termination was futility, not inadequate recruitment ④ clause 82 does not apply, so it is not counted. No listed item applies.
Why this is classified as D (34)
The 885-participant publicly funded hard-clinical-outcome RCT was null. It had neither a formal interim stopping boundary nor recruitment-shortfall termination, so axis 6 has no defect and the result remains D, 34.
Counterpoint. Nonfatal serious adverse events were 0.63 versus 0.62 per person-year and deaths were 28 versus 30, with no significant safety harm.
Rejudgment record. Source checked — Null STATCOPE primary exacerbation rate; DSMB futility stopping without a formal boundary
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced annual COPD exacerbation rate | D | Rates were 1.36 versus 1.39. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| STATCOPE | Multicenter randomized double-blind placebo-controlled trial | 885 | Public funding from NHLBI and CIHR | Annual COPD exacerbation rate | 1.36±1.61 vs 1.39±1.73 per person-year, P=0.54 | Pivotal publicly funded RCT |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Simvastatin × Exacerbations in Moderate-to-Severe COPD at High Risk — Evidence Grade D·34. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/simvastatin-high-risk-copd-exacerbations/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.